Global healthcare venture capital firm Omega Funds has closed its eighth fund at $647 million, surpassing its initial target of $600 million. The oversubscribed Omega Fund VIII, L.P., received backing from both new and existing investors. It will continue to invest in innovative life sciences companies in the U.S. and Europe that address critical medical needs.
Since 2004, Omega Funds has raised $2.5 billion to support entrepreneurs developing groundbreaking products across various therapeutic areas, including oncology, immunology, rare diseases, medical devices, and precision medicine. Building on its previous successes, Fund VIII has contributed to 52 products reaching the market, with Omega’s investments leading to 50 M&A exits and 47 public listings.
Recent notable exits include SoniVie (acquired by Boston Scientific), Scorpion Therapeutics (acquired by Eli Lilly), Kestra Medical Technologies, Beta Bionics, Upstream Bio, Bicara Therapeutics, Morphic Therapeutic (acquired by Eli Lilly), EyeBio (acquired by Merck), Imago BioSciences (acquired by Merck), Amunix Pharmaceuticals (acquired by Sanofi), and Chord Therapeutics (acquired by Merck).
KEY QUOTES:
“We are very grateful to our investors for the support and trust, particularly given this exceptionally challenging fundraising environment. By exceeding its target size, Fund VIII is a recognition of our investment strategy and track record of consistent exits across market cycles. We appreciate the partnership from both our longstanding and new limited partners.”
Otello Stampacchia, Founder and Managing Director of Omega Funds
“As with prior funds, Fund VIII will support management teams in the U.S. and Europe through company creation, early venture rounds, and later-stage financings. We believe our broad investment strategy is well-positioned for navigating this period of macro and policy uncertainty. We look forward to contributing our capital, expertise, and network connectivity in partnering with entrepreneurs, founders, co-investors, and the broader community to transform the standards of care for severe diseases.”
Francesco Draetta, Managing Director of Omega Funds
